Un abonnement à JoVE est nécessaire pour voir ce contenu. Connectez-vous ou commencez votre essai gratuit.
1MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences,University of Dundee, 2The Michael J. Fox Foundation for Parkinson’s Research, 3Department of Medical and Molecular Genetics,Indiana University School of Medicine, 4Morton and Gloria Shulman Movement Disorders Centre and the Edmond J. Safra Program in Parkinson’s Disease, Toronto Western Hospital,University of Toronto, 5Division of Cell Signalling and Immunology, School of Life Sciences,University of Dundee, 6Division of Molecular and Clinical Medicine, School of Medicine, Ninewells Hospital and Medical School,University of Dundee
Chapitres
- 00:01Introduction
- 00:48Neutrophil Isolation from Human Peripheral Blood
- 07:18LRRK2 Kinase Inhibitor Treatment
- 10:33Résultats
- 12:14Conclusion
Mutations in the leucine rich repeat kinase 2 gene (LRRK2) cause hereditary Parkinson’s disease. We have developed an easy and robust method for assessing LRRK2-controlled phosphorylation of Rab10 in human peripheral blood neutrophils. This may help identify individuals with increased LRRK2 kinase pathway activity.
